Pharma's Most Impervious Pipeline

is trading at less than 8 times forward earnings, which puts it in the same "cheap" territory as Eli Lilly (NYSE: LLY Teva, on the other hand, has Copaxone, which accounts for $3.3 billion in annual sales, under patent until 2014. Even a worst-case...